anti trefoil factor 2 tff2  (Proteintech)

Journal: Gastro Hep Advances

Article Title: Helicobacter pylori Exploit Short-Chain Fatty Acids-Induced CAPZA1 Overexpression to Emerge CD44v9-Positive Stemness

doi: 10.1016/j.gastha.2025.100860

Figure Lengend Snippet: Stem cell characteristics of CD44v9-positive cells induced by H pylori G27 strains (CagA-positive H pylori ) infection in the presence of butyrate (But). Immunofluorescence analysis of colocalization between CD44v9 and stem cell markers (LGR5, KLF5, and SALL4) in mucosoids derived from the gastric corpus and antrum of mice infected with H pylori G27 strains (CagA-positive H pylori ) or H pylori G27 cag PAI-deletion mutant strains (Δ cag PAI) in the presence of But. Colocalization of CD44v9 and the SPEM marker TFF2 was also assessed. Scale bar = 50 μm.

Article Snippet: The following antibodies were used for fluorescence immunocytochemistry: anti-CAPZA1 (OTI2G4) (Thermo Fisher Scientific, cat# MA5-25093; 1:500 or Abcam, Cambridge, UK, cat# ab166892; 1:500), anti-CD44v9 (Cosmo Bio, Tokyo, Japan, cat# CAC-LKG-M001; 1:500), anti-CagA (Austral Biologicals, cat# HPM-5001–5; 1:500), anti-LGR5 (Atlas antibodies, Stockholm, Sweden, cat# HPA012530; 1:200), anti-KLF5 (GeneTex, Irvine, CA, cat#GTX103289; 1:200), anti-SALL4 (Abcam, cat# ab29112; 1:200), and anti-trefoil factor 2 (TFF2) (Proteintech, Wuhan, China, cat# 13681-1-AP; 1:200).

Techniques: Infection, Immunofluorescence, Derivative Assay, Mutagenesis, Marker

Journal: Frontiers in Oncology

Article Title: TFF2, a novel serum diagnostic biomarker for early pancreatic cancer

doi: 10.3389/fonc.2025.1633069

Figure Lengend Snippet: Identification of serum markers for early pancreatic cancer. (A) The volcano plots of DEGs. (B) Venn diagram showing 6 intersection genes from upregulated DEGs in GSE43288 and the TCGA_PAAD cohort. (C) Venn diagram showing 3 intersection genes from the DEGs and genes encoding exocrine proteins of the HPA database. (D) Gene expression levels of TFF2 in different cancers across TCGA. (E) Gene expression levels of TFF2 in different pathological stages from GSE43288 . (F) ROC analysis illustrating the diagnostic performance of TFF2 and tumor markers for PanIN and PC.

Article Snippet: An ELISA kit for human TFF2 (Cusabio) was utilized to quantify serum TFF2 levels in patients with PC, CCA, duodenal adenocarcinoma, ampullary adenocarcinoma, and healthy individuals following the manufacturer’s protocol.

Techniques: Gene Expression, Diagnostic Assay

Journal: Frontiers in Oncology

Article Title: TFF2, a novel serum diagnostic biomarker for early pancreatic cancer

doi: 10.3389/fonc.2025.1633069

Figure Lengend Snippet: Validation of TFF2 expression pattern by single-cell analysis. (A, B) Cluster diagrams based on cell types and sample sources. (C) Feature plot of TFF2 expression by single-cell analysis. (D) Violin plot illustrating the distribution of TFF2 expression at the single-cell level.

Article Snippet: An ELISA kit for human TFF2 (Cusabio) was utilized to quantify serum TFF2 levels in patients with PC, CCA, duodenal adenocarcinoma, ampullary adenocarcinoma, and healthy individuals following the manufacturer’s protocol.

Techniques: Biomarker Discovery, Expressing, Single-cell Analysis

Journal: Frontiers in Oncology

Article Title: TFF2, a novel serum diagnostic biomarker for early pancreatic cancer

doi: 10.3389/fonc.2025.1633069

Figure Lengend Snippet: Validation of the diagnostic efficacy of TFF2. (A–C) Comparison of TFF2 mRNA expression across multiple datasets: in normal and PC tissues ( GSE15471 , GSE16515 , and GSE32676 ), CCA tissues ( GSE26566 ), and HCC tissues ( GSE89377 ). (D–G) Statistical analyses and ROC curve assessments of TFF2 and tumor markers at the mRNA level, comparing PC with benign controls, CCA, HCC, and periampullary adenocarcinoma. Data are shown as the mean ± SEM. Significance is indicated as follows: * P< 0.05, ** P< 0.01, *** P< 0.001; ns represents no significant difference.

Article Snippet: An ELISA kit for human TFF2 (Cusabio) was utilized to quantify serum TFF2 levels in patients with PC, CCA, duodenal adenocarcinoma, ampullary adenocarcinoma, and healthy individuals following the manufacturer’s protocol.

Techniques: Biomarker Discovery, Diagnostic Assay, Comparison, Expressing

Journal: Frontiers in Oncology

Article Title: TFF2, a novel serum diagnostic biomarker for early pancreatic cancer

doi: 10.3389/fonc.2025.1633069

Figure Lengend Snippet: Validation of Diagnostic efficacy of serum TFF2. (A) Serum TFF2 expression levels from normal controls, periampullary adenocarcinoma patients, and PC patients. Data are shown as the mean ± SEM. Significance is indicated as follows: * P< 0.05, ** P< 0.01, *** P< 0.001; ns represents no significant difference. Significance is indicated as follows: ***P<0.001; ns represents no significant difference. (B, C) ROC analysis results for serum TFF2, CA199, CEA and the combined biomarker panel in discriminating PC patients from healthy individuals and periampullary adenocarcinoma patients, respectively.

Article Snippet: An ELISA kit for human TFF2 (Cusabio) was utilized to quantify serum TFF2 levels in patients with PC, CCA, duodenal adenocarcinoma, ampullary adenocarcinoma, and healthy individuals following the manufacturer’s protocol.

Techniques: Biomarker Discovery, Diagnostic Assay, Expressing